Hypoxia classifier in cervical cancer
Introduction
Improvements in the therapy of locally advanced cervical cancer are highly needed since many patients experience local or systemic relapse and severe side effects after treatment (1, 2) . Tumor hypoxia is an adverse factor associated with radiation resistance and metastasis (3) (4) (5) . Thus, hypoxia is both a potential marker for predicting risk of recurrence and a target in new treatment strategies combined with radiotherapy. Adjuvant hypoxiamodifying treatment has been shown to improve the efficacy of radiotherapy in cervical cancer (6) , and combination trials to find the optimal drug have been performed (7, 8) and are underway (ClinicalTrials.gov identifier NCT02394652). In many trials, difficulties in detecting drug effects and toxicity are major problems, since patients are randomized to the adjuvant treatment without knowledge of the hypoxia status of the tumor (9). Development of methods for classifying patients according to the hypoxia status is therefore an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit. Gene expression signatures can provide an indirect measure of the hypoxia level in a tumor through the cellular transcriptional response to low oxygen concentrations, and therefore be of value for classifier development. Several hypoxia signatures have been constructed in different tissues (10-18), but a common cancer signature seems difficult to derive (19) . The only hypoxia signature presented for cervical cancer was discovered in our previous work by combining global gene expression profiles and dynamic contrast enhanced (DCE)-magnetic resonance imaging (MRI) of the same patients (20) . The amplitude A Brix in the Brix pharmacokinetic model (21) extracted from DCE-MR images was found by us and others to reflect hypoxia in cervical tumors (20, 22) . The signature contained 31 hypoxiaresponsive genes for which expression correlated with the patient derived A Brix data (20) . This approach increased the likelihood of finding a signature that described a clinically relevant hypoxic phenotype. Both DCE-MRI and the 31-gene expression signature may have potential as a tool for assessing hypoxia in cervical cancer (20, 22) . A current major limitation of MRI-based classifiers is, however, the lack of image standardization across MR machines (23, 24) . Gene expression assays are easier to standardize, and multi-gene signatures have shown to be useful for guiding treatment decisions in many cancer types, like breast and prostate cancer (25, 26) . Further, gene signatures provide information that may increase the understanding of resistance mechanisms at play in individual tumors and thereby means for choosing the optimal targeted therapy in an individualized, combined radiotherapy regime (27) .
Today, imaging and genomics appear as distinct facets in the treatment decision support system. Development of a direct link between the two disciplines would facilitate implementation of a multifactorial tool for a more accurate response prediction (24, 28) . In the present work, we aimed to prepare our signature for clinical use by constructing an image associated, dichotomous hypoxia gene classifier with a predefined threshold for classification that could be utilized in a prospective setting. By integrative analysis of A Brix and gene expression profiles, we identified genes in the signature that combined showed the optimal discrimination between more and less hypoxic tumors at the time of diagnosis.
The power of this novel approach was demonstrated by the presentation of a hypoxia gene classifier that was reflected in DCE-MR images and showed prognostic impact across cohorts and test assays.
Research. 
Materials and Methods

Patient cohorts, tumor specimens, and treatment
Totally 281 patients with locally advanced squamous cell carcinomas of the uterine cervix, prospectively recruited to our chemoradiotherapy protocol at the Norwegian Radium
Hospital from 2001 to 2012, were included. Fifty-eight patients enrolled during the same period, were not included because the tumor biopsies contained less than 50% malignant cells in hematoxylin and eosin stained sections from the central part of the specimen. The patients constituted three independent cohorts; training cohort (n=42), cohort 1 (n=108), and cohort 2 (n=131) (Fig. 1, Supplementary Table S1 ). The patients were divided into the different cohorts based on the Illumina beadarray version they were assayed by, i.e. WG-6 v3 (training cohort, cohort 1) or HT-12 v4 (cohort 2). The patients assayed by the WG-6 arrays were further divided into the training cohort consisting of the patients with available Tumor volume was determined from diagnostic MR images. Pathologic lymph nodes at diagnosis were also detected by MRI, or in a few cases by computed tomography (CT),
DCE-MRI
Diagnostic DCE-MR images of 64 patients (42 patients in the training cohort, 17 patients in cohort 2 and 5 patients with adenocarcinoma or adenosquamous carcinoma) were applied for construction and validation of the classifier (Fig. 1) . Imaging was performed using a 1.5
T Signa Horizon LX tomography (GE Medical Systems, Milwaukee, WI) with a pelvicphased array coil. The MR examination included standard T1 and T2-weighted imaging followed by DCE-MRI with 0.1 mmoL/kg body weight Gd-DTPA (Magnevist ® , Schering, Berlin, Germany) administered as a fast bolus injection, as described (31) . Hypoxia classifier in cervical cancer strongest association to outcome in previous work (20) , was calculated and used as an image parameter reflecting hypoxia.
Cell culture
Hypoxia-induced genes were assessed in eight human cervical cancer cell lines from the American Type Culture Collection; HeLa, SW756, C-33 A, C-4I, ME-180, HT-3, SiHa, and CaSki, and used for the first refinement of the signature. Hypoxia classifier in cervical cancer the software provided by the manufacturer (Illumina Inc.), and log2-transformed data were used in the analyses. The data were deposited in the gene expression omnibus (GEO) database (GSE72723).
Gene expression by reverse transcription quantitative PCR (RT-qPCR)
The transferability of the classifier across assay platforms was tested in a RT-qPCR assay on 74 patients from the training cohort and cohort 1, using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). Genomic DNA was removed from the RNA samples by using the DNA-free™ Kit (Ambion, Austin, TX), according to the manufacturer's description. Table S2 ). Minus reverse transcriptase controls were tested for residual genomic DNA for all TaqMan assays. Nontemplate controls without RNA into the cDNA synthesis were included. All negative controls had undetermined quantification cycle (C q ). The data were analyzed using the comparative 
Gene expression classifier
To construct a gene classifier for separating the more and less hypoxic tumors, a previously presented algorithm (11) was utilized with small modifications, as described in Supplementary Document 1. A Brix was used as a measure of hypoxia, and the construction was performed blinded to the clinical outcome. In brief, the classifier consisted of three parameters for each gene included; i.e., the mean expression of the gene in a group of more hypoxic tumors (
) and a group of less hypoxic tumors ( ) and its common variance ( ) across both groups. The classifier parameters were determined as described below based on the training cohort, which was assumed to represent a typical patient cohort, and tabulated for further use in the classification of new tumors. 
Statistics
Clinical endpoints were progression free survival (PFS), locoregional control (LRC) and disease-specific survival (DSS) for follow-up until 5 years. For patients with shorter than 5 years of follow-up, status was assessed at October 3rd 2014. Patients were censored at their last appointment or at 5 years. For PFS, time from diagnosis to disease-related death or first event of relapse was used, LRC was defined as control within the irradiated pelvis, and DSS was defined as not dead from cervical cancer. Deaths within 2 years after inclusion were regarded as disease-related unless another cause was documented. Hypoxia classifier in cervical cancer follow-up period of 5 years. Gray's test was used to assess differences between cumulative incidence curves. COX uni-and multivariate proportional hazard (PH) analyses were performed, and assumptions of PHs were tested graphically using log-minus-log plots.
Existing clinical markers, i.e. tumor volume, FIGO stage, and lymph node involvement, were used as covariates to evaluate the independent prognostic value of the classifier.
Significance level was 5%, and all P-values were two-sided. COX PH analyses were performed in SPSS Statistics 21, while all other analyses were performed using R (33) version 3.1.1.
Results
Classifier construction
The classifier was based on a 31-gene signature identified in previous work ( Fig. 1) (20) . To enrich for genes specific for hypoxia in cervical cancer, the 31-gene signature was first reduced to include only the 17 genes with at least two-fold up-regulation by hypoxia in at least one out of eight cervical cancer cell lines (Supplementary Table S3 ). These 17 genes served as basis for classifier construction in the training cohort. We found an optimal separation of the cohort into 11 more hypoxic (low A Brix ) and 31 less hypoxic (high A Brix ) tumors ( Fig Based on the expression levels of the six genes in a new tumor and the classifier parameters, , , and for each gene ( 
showed differences in the A Brix map (examples in Fig. 2C right) , and D less -D more showed a significant association to A Brix (P < 0.001; ρ = -0.66; n = 42; Fig. 2C left) that was just as strong as for the original 31-gene signature (20) represented by a gene score (P < 0.001; ρ = -0.68; n = 42). The association to A Brix was thus retained after reducing the signature and constructing the classifier.
Validation across cohorts and array generations
The prognostic significance of the classifier was evaluated in two independent data sets based on different Illumina array generations (WG-6 and HT-12; Fig. 1 ). For cohort 1, assayed using the WG-6 arrays, 40 out of 108 patients (37%) were classified with a more hypoxic tumor. In this group, a significantly higher cumulative incidence of recurrence was found than in the less hypoxic group (40% vs. 15% at 5 years; P = 0.0035; hazard ratio (HR), 3.06; 95% confidence interval (CI), 1.39-6.74; Fig. 3A) . Thus, the classifier could separate the patients into two groups with different outcome similarly to the original 31-gene hypoxia score (Fig. 3B) , showing that the prognostic value of the signature was retained in the 6-gene classifier.
Out of 131 tumors in cohort 2, assayed by HT-12 arrays, 42 (32%) were classified as more hypoxic, and the patients in the more hypoxic group had a significantly higher risk of relapse than the others (36% vs. 20% at 5 years; P = 0.014; HR, 2.42; 95% CI, 1.20-4.90; Fig. S1 ).
Validation across platforms
To further evaluate its robustness, a technical transfer of the classifier to RT-qPCR was performed for 74 patients (Fig. 1) . For 19 of the 74 samples, gene expression measurements for KCTD11 and/or UPKIA were unsuccessful. The robustness of the classifier when lacking UPK1A and/or KCTD11 as compared with the full 6-gene classifier was estimated from the Illumina data of the 281 patients included in the study. Prognostic significance was obtained for all four combinations of the 4-6 genes (Supplementary Table   S6 ). All 74 patients could therefore be classified based on the data of 4-6 genes. The Hypoxia classifier in cervical cancer expression levels of the six classifier genes showed a strong correlation between the RTqPCR and Illumina WG-6 based measurements, with a Spearman's rank correlation coefficient above 0.7 ( Supplementary Fig. S2 ). Moreover, there was a significant correlation between the Illumina-based and RT-qPCR-based classifications (P < 0.001; ρ = 0.74; Fig.   3E ). Out of 74 patients, 56 (75.7%) were classified to the same group by the RT-qPCR and Illumina assay (Supplementary Table S7) , showing reproducibility of the classifier using two different assays (P < 0.001). For the remaining 18 patients, 11 were classified with a more hypoxic tumor by Illumina and not by RT-qPCR, while 7 were classified with a more hypoxic tumor by RT-qPCR and not by Illumina. For many of the patients classified differently with the two methods, D less -D more was close to the border between the two groups (Fig. 3E) .
Moreover, the few patients with missing RT-qPCR data for one or two genes were not classified differently as compared to the others (Fig. 3E) , illustrating the robustness of the classifier in that missing values can be tolerated.
The 26 patients (35%) classified to the more hypoxic group by RT-qPCR, had a poor prognosis compared with the others (58% vs. 35% at 5 years; P = 0.035; HR = 2.12; CI, 1.06-4.26; Fig. 3F ), and the separation between the groups were similar to that obtained with Illumina data for the same patients (58% vs. 34% at 5 years; Supplementary Fig. S3A ).
Also the A Brix -association could be validated across the platforms, although the correlation was somewhat stronger for Illumina WG-6 (P < 0.001; ρ = -0.70; n = 32) than RT-qPCR (P = 0.003, ρ = -0.51; n = 32) ( Supplementary Fig. S3B-C) .
Comparison with clinical markers
To compare classifier performance with existing clinical markers, all cohorts were merged (Fig. 1) . Out of 281 patients, 100 (36%) were classified with a more hypoxic tumor. The Hypoxia classifier in cervical cancer probabilities of having high tumor stage, large tumor volume, or lymph node involvement were significantly higher for the more hypoxic group compared with the less hypoxic group (Table 2) . Among the patients in the more hypoxic group, 36% had a stage 3A-4A tumor, 63% had a tumor volume above the median value of 36.8 cm 3 and 52% had lymph node involvement at the time of diagnosis as compared to 24% (P = 0.037), 43% (P = 0.0019) and 38% (P = 0.032) in the less hypoxic group.
In univariate COX regression analyses, both the clinical markers and 6-gene classifier showed prognostic significance regardless of endpoint, with HRs above 2 (Table 3) .
Moreover, the significance of the classifier was retained in multivariate analyses, with HRs of 2.12 (PFS), 2.62 (LRC), and 2.12 (DSS) ( Table 3) . Thus, even though there were associations between hypoxia classification and the other markers, the classifier emerged as an independent prognostic factor at all endpoints. which MR image guided brachytherapy has been implemented in our hospital and replaced brachytherapy based on 2D X-ray imaging (36) . Moreover, the second cohort was analyzed with another Illumina array generation, which required data transformation prior to classification. Successful utilization of the classifier was also demonstrated in a RT-qPCR assay, with samples collected over a period of 8 years. In all tests of the classifier, not only its prognostic impact but also its association to A Brix was retained. Notably, the classifier seemed to be more robust than the original 31-gene score, for which association to clinical outcome failed to reach statistical significance in the second cohort.
The classifier was associated with outcome independent of conventional markers for PFS, LRC, and DSS, and may provide information about disease progression that is not covered by current diagnostics. Even though FIGO is a strong prognostic factor in cervical cancer, the classifier emerged as an independent prognostic factor. Importantly, through its biological fundament, the classifier could be a well needed tool for selecting patients to hypoxia-modifying adjuvant therapy and to avoid added side effects to those who are not expected to respond. The latter scenario is important because the risk of damage to critical pelvic organs is already a significant challenge in the conventional chemoradiotherapy (1, 2,   37 ). In addition, many patients classified with hypoxia in our work had a high risk of both failure and side effects by conventional markers, presented with large tumor, lymph node involvement and/or stage 3 or 4 disease. These patients belong to a group where the gain of treatment improvements would be particularly high (1, 2). A higher incidence of lymph node positive patients in the more hypoxic group and a weak correlation between hypoxia 
and tumor size have been found in earlier cervical cancer studies using oxygen electrodes to assess hypoxia (4, 38, 39) , in accordance with our findings.
Hypoxia gene signatures have been constructed in other tissue types by different approaches, and some signature genes are in common. Among 32 signatures reviewed by Harris et al. (19) , two out of our six classifier genes, P4HA2 and ERO1A, are among the 20 most frequently appearing ones. The presence of common genes indicates that it might be possible to identify a signature that is applicable in different tumor sites, which has indeed been demonstrated in some cases (10, 15, 17, 40, 41) . However, although the head and neck cancer signature by Eustace et al. identified patients with laryngeal cancer who seemed to benefit from adjuvant hypoxia-modifying treatment, this was not the case when the signature was used on patients with bladder cancer (12) . Moreover, when comparing six of the previously published hypoxia gene signatures (10-15) with the classifier genes in the present work, we found that our genes had the strongest prognostic impact in the cervical cancer data set (Supplementary Document 3) . In particular, only the signature developed in breast cancer by Hu et al. (15) showed a significant association to outcome (P = 0.026) in COX PH univariate analysis. Out of our classifier genes, only KCTD11 and P4HA2 were present in three (10-12) or one (11) of the six signatures, respectively. These results support the view that there are molecular differences in the aggressive hypoxic phenotype across cancers (19) , and that cancer-type specific hypoxia gene classifiers are more effective (18) . Further, although some of the other signatures were statistically significantly correlated with A Brix (Supplementary Document 3) , the signature of our classifier genes showed a stronger A Brix -association, and was thus the best one for describing the aggressive phenotype reflected in the DCE-MR images of cervical cancer.
Research. This limitation of our work needs to be addressed before a multifactorial tool based on the combined use of our classifier and imaging can be developed for clinical use. Further, the predictive value of the classifier in identifying the tumors that will benefit from hypoxiamodifying treatment remains to be shown. Two head and neck cancer signatures have shown promise as predictive hypoxia biomarkers (12, 42, 43) , illustrating the potential of gene signatures for hypoxia stratification. For cervical cancer, the optimal hypoxia-targeting drug has yet to be defined (7, 8) , and careful considerations in the study design have to be done due to toxicity problems. Future work should involve multicenter studies for verifying the classifier's prognostic value, and testing the predictive impact in a clinical trial.
Research. The classifier genes provide biological insight into the disease that may aid the choice of drugs for combination trials. STC2, P4HA2 and ERO1A have been identified as direct target genes of the hypoxia inducible factor 1 (HIF1) (44-47). In addition, DDIT3 (48), ERO1A (49) , and STC2 (50) may be activated through the unfolded protein response (UPR). Thus, both HIF1 and UPR pathways, which are major oxygen-sensitive pathways promoting hypoxia tolerance (51), might be involved in mediating the aggressive phenotype reflected by our classifier. Several HIF1 and UPR targeting drugs are currently under development (48, (52) (53) (54) and could be relevant to evaluate in the selected patients. confidence intervals for hazard ratio (HR), P-values from Gray's test and number of patients at risk are indicated; death from other causes than cervical cancer was included as a competing event (n= 9 in cohort 1 and 3 in cohort 2).
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